CCL2 DNA vaccine to treat renal disease

Authors

Debbie Watson, Children’s Hospital at WestmeadFollow
Guoping Zheng, University of Sydney
Huiling Wu, Royal Prince Alfred HospitalFollow
Yuan Min Wang, Children’s Hospital at Westmead
Yiping Wang, University of Sydney
David C. H Harris, University of Sydney
S I. Alexander, Children’s Hospital at WestmeadFollow

RIS ID

26757

Publication Details

Watson, D., Zheng, G., Wu, H., Wang, Y., Wang, Y., Harris, D. C. H. & Alexander, S. I. (2009). CCL2 DNA vaccine to treat renal disease. The International Journal of Biochemistry and Cell Biology, 41 (4), 729-732.

Abstract

CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.